Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs. Recent systematic reviews and large-scale registry studies demonstrated similar rates of overall mortality and myocardial infarction for patients treated with either DESs or bare-metal stents during long-term follow-up. Careful selection of stent type according to patient and lesion characteristics as well as monitoring of adherence to dual antiplatelet therapy could maximize the therapeutic potential of these devices. The purpose of the present Review is to provide the reader with an overview of the benefits and risks of first-generation DESs that could help physicians select the most appropriate stent type for each patient.

Original publication

DOI

10.1038/ncpcardio1189

Type

Journal article

Journal

Nat Clin Pract Cardiovasc Med

Publication Date

06/2008

Volume

5

Pages

316 - 328

Keywords

Coronary Restenosis, Coronary Thrombosis, Drug-Eluting Stents, Humans, Immunosuppressive Agents, Incidence, Paclitaxel, Platelet Aggregation Inhibitors, Risk Factors, Sirolimus, Time Factors, Treatment Outcome